Scynexis Reports $20.6M Revenue, Cuts Loss to $(0.17) EPS on Strategic GSK Deal
SCYX sits 37% above its 52-week low of $0.565.
Summary
Scynexis reported its 2025 annual results from its 10-K filing, showing total revenue of $20.6 million and a net loss of $(0.17) per share. This represents a significant increase from $3.7 million revenue and a substantial improvement from $(0.44) EPS in 2024. The revenue growth was primarily driven by a $17.2 million cumulative catch-up related to a license agreement with GSK, which involved out-licensing BREXAFEMME and one-time payments totaling $24.8 million. The company is strategically refocusing on its next-generation antifungal program, SCY-247, which has completed Phase 1 studies and is planning a Phase 2 study in 2026. These results indicate a material improvement in financial performance and a clear strategic shift, providing capital and allowing the company to concentrate resources on its pipeline. Investors will monitor the progress of the SCY-247 Phase 2 study and further details on the collaboration with GSK.
At the time of this announcement, SCYX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $0.57 to $1.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.